Results 251 to 260 of about 1,467,646 (404)

Design of a prodrug bispecific antibody masked by a functional molecule for lymphocyte activation for cancer therapy. [PDF]

J Biol Eng
Miura D, Kato Y, Yasunaga M, Kumagai I, Asano R.   +4 more
europepmc   +1 more source

Induction of long-lasting antitumor immunity by concomitant cell therapy with allogeneic lymphocytes and trifunctional bispecific antibody [PDF]

, 2008
Shoshana Morecki, Horst Lindhofer, Elena Yacovlev, Yael Gelfand, Peter Ruf, Shimon Slavin   +5 more
openalex   +1 more source

Furmonertinib in uncommon EGFR‐mutated non‐small cell lung cancer with central nervous system metastases: A retrospective cohort study

International Journal of Cancer, Volume 157, Issue 5, Page 954-963, 1 September 2025.
What's new? Mutations in EGFR are the most frequently detected driver mutations in non‐small cell lung carcinoma (NSCLC), and two common mutations account for 75%–90% of these. The remaining 10%–25% are uncommon mutations, a heterogeneous set of genetic changes that do not necessarily respond well to treatment.
Yuwen Xie, Hehui Fang, Wanwan Cheng, Ting Xu, Shu Xu, Chuanyong Yu, Yong Liu, Shencun Fang   +7 more
wiley   +1 more source

A broad antibody with enhanced HIV-1 neutralization via bispecific antibody-mediated prepositioning. [PDF]

Nat Commun
Kim S, Radford CE, Xu D, Zhong J, Do J, Pham DM, Travisano KA, Filsinger Interrante MV, Bruun TUJ, Rezek V, Wilder B, Palomares M, Seaman MS, Kitchen SG, Bloom JD, Kim PS.   +15 more
europepmc   +1 more source

Construction of Optimized Bispecific Antibodies for Selective Activation of the Death Receptor CD95 [PDF]

, 2008
Tanja Herrmann, Ludger Große‐Hovest, Tina Otz, Peter H. Krammer, Hans‐Georg Rammensee, Gundram Jung   +5 more
openalex   +1 more source

Targeted cancer immunotherapy via combination of designer bispecific antibody and novel gene-engineered T cells [PDF]

, 2014

core   +1 more source

Alternative Immunosuppression in Acquired Haemophilia A

Haemophilia, EarlyView.
Jayna Mistry, Gillian Lowe, Will Lester, Charles Percy   +3 more
wiley   +1 more source

Transforming Growth Factor‐Beta Signaling in Cancer: Therapeutic Implications, Challenges, and Pathways to Progress

MedComm – Oncology, Volume 4, Issue 3, September 2025.
TGF‐β inhibition is emerging as a promising cancer therapy, yet translating laboratory success to bedside implementation has suffered significant setbacks. The associated challenges include adverse drug reactions, inadequate predictive models, and activation of alternative signaling pathways.
Faizah A. Alabi, Izuchukwu F. Okpalanwaka, Adenike Oyegbesan, Ebenezar Okoyeocha, Mariam Oladejo, Sikiru O. Imodoye   +5 more
wiley   +1 more source

Targeting CD16A on NK cells and GPC3 in hepatocellular carcinoma: development and functional validation of a therapeutic bispecific antibody. [PDF]

Front Immunol
Chen L, Zhu Y, Feng M, Zuo D, Chen G, Ji K.   +5 more
europepmc   +1 more source

Novel bispecific antibody causes tumor regression in patients with non-Hodgkin lymphoma [PDF]

, 2008

openalex   +1 more source